» Articles » PMID: 9809552

DNA Vaccines with Single-chain Fv Fused to Fragment C of Tetanus Toxin Induce Protective Immunity Against Lymphoma and Myeloma

Overview
Journal Nat Med
Date 1998 Nov 11
PMID 9809552
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.

Citing Articles

Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model.

Kondou K, Suzuki T, Chang M, Takaku H J Biol Eng. 2019; 13:77.

PMID: 31649751 PMC: 6805443. DOI: 10.1186/s13036-019-0207-y.


Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines.

Shrestha A, Wijesundara D, Masavuli M, Mekonnen Z, Gowans E, Grubor-Bauk B Vaccines (Basel). 2019; 7(2).

PMID: 31052178 PMC: 6630607. DOI: 10.3390/vaccines7020038.


scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.

Zanetti B, Ferreira C, de Vasconcelos J, Han S Gene Ther. 2019; 26(10-11):441-454.

PMID: 30770895 DOI: 10.1038/s41434-019-0062-y.


Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.

Elsayed H, Nabi G, McKinstry W, Khoo K, Mak J, Salazar A J Virol. 2018; 92(14).

PMID: 29743369 PMC: 6026751. DOI: 10.1128/JVI.00141-18.


Targeting Head and Neck Cancer by Vaccination.

Wang C, Dickie J, Sutavani R, Pointer C, Thomas G, Savelyeva N Front Immunol. 2018; 9:830.

PMID: 29740440 PMC: 5924779. DOI: 10.3389/fimmu.2018.00830.